Addyi Cost in Nebraska 2026: Flibanserin Price, Insurance, and Compounding Options

What Does Addyi Actually Cost in Nebraska in 2026?

The retail cash price for a 30-tablet supply of branded Addyi (flibanserin 100 mg) at Nebraska pharmacies runs approximately $880 per month in 2026. That figure reflects the Sprout Pharmaceuticals wholesale acquisition cost passed through to retail, and it has not dropped meaningfully since the drug's 2015 launch. Patients paying cash without any assistance program face the full $880 charge.

Sprout Pharmaceuticals maintains a mandatory Risk Evaluation and Mitigation Strategy (REMS) program for Addyi. Prescribers and dispensing pharmacies must complete REMS certification before the drug can be prescribed or dispensed. That certification requirement limits which Nebraska pharmacies can stock the drug, meaning price shopping across multiple retail locations is not always straightforward.

The FDA's original approval of flibanserin was based on three key Phase 3 trials. In the BEGONIA trial (N=949), women randomized to flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo, with a mean increase of 0.5 SSEs per 28-day period versus placebo (P<0.001) [1]. That modest but real benefit is the clinical foundation justifying a drug that costs $880 per month for Nebraska patients paying out of pocket.

For patients without any coverage or savings card, generic or compounded flibanserin sourced through a licensed 503A compounding pharmacy may be the only accessible route. We cover that option in detail below.

Nebraska Medicaid Does Not Cover Addyi in 2026

Nebraska Medicaid (Heritage Health) does not cover flibanserin as of 2026. The drug is excluded from the Nebraska Medicaid preferred drug list, and no prior authorization pathway currently exists to obtain coverage through the state program.

This exclusion is not unique to Nebraska. Most state Medicaid programs exclude Addyi, partly because the drug's clinical effect size is modest and partly because the program's pharmacy benefit prioritizes conditions associated with measurable morbidity and mortality. The FDA's own prescribing information notes that the net benefit over placebo, while statistically significant, is "small" [2], which influences formulary decisions at the state level.

Nebraska Medicaid does cover treatment for related comorbidities. If low sexual desire is secondary to a treatable condition such as major depressive disorder or hypothyroidism, Medicaid may cover antidepressants or thyroid hormone replacement that could address the underlying driver. The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends ruling out thyroid disease, hyperprolactinemia, and androgen deficiency before initiating pharmacotherapy for HSDD [3].

Patients on Nebraska Medicaid with a confirmed HSDD diagnosis should ask their provider to document the evaluation pathway clearly, because private supplemental plans sometimes purchased alongside Medicaid may have separate formularies with different coverage rules.

Which Private Insurance Plans Cover Addyi in Nebraska?

Commercial insurance coverage for Addyi in Nebraska is inconsistent across carriers. No Nebraska-specific formulary mandate requires coverage of flibanserin, so each insurer sets its own policy.

Plans that do cover Addyi typically place it on Tier 3 or Tier 4, meaning the patient still pays a substantial copay, often $50 to $200 per month after the deductible is met. The FDA's drug label specifies flibanserin only for premenopausal women with acquired, generalized HSDD, and insurers frequently require documentation of that specific diagnosis before approving a claim [2].

To improve the odds of insurance approval in Nebraska:

1. Confirm the diagnosis code (ICD-10 F52.0, hypoactive sexual desire dysfunction) appears on the prescription and supporting chart notes.
2. Ask your prescriber to submit a letter of medical necessity that references the BEGONIA trial results and the FDA label indication.
3. File a formal appeal if the first prior authorization request is denied. Insurers overturn denials in a meaningful percentage of cases when clinical documentation is thorough.

A 2019 analysis published in the Journal of Sexual Medicine found that physician knowledge of Addyi's REMS requirements was inversely associated with prescribing rates, suggesting that administrative burden, not just clinical skepticism, suppresses prescribing [4]. That same administrative friction affects insurance approval timelines.

How the Sprout Pharmaceuticals Savings Card Works in Nebraska

The Sprout savings card (sometimes called the "Addyi Access Program") is available to commercially insured patients in Nebraska who meet eligibility criteria. It is not available to patients covered by federal or state government programs, including Nebraska Medicaid, Medicare, or Tricare.

Eligible patients may pay as little as $0 per month through the savings card, though the program terms change periodically. The savings card functions as a secondary payer: your commercial insurance is billed first, and the savings card covers a portion of the remaining balance up to a defined annual maximum.

Steps to use the savings card in Nebraska:

1. Obtain a prescription from a REMS-certified prescriber.
2. Confirm your dispensing pharmacy is REMS-certified (the Addyi website maintains a locator).
3. Enroll in the savings card program at the Sprout website before filling your first prescription.
4. Present the card at the pharmacy alongside your insurance card.

The program's eligibility rules bar patients whose insurance plan has carved out the savings card benefit, a practice sometimes called "copay accumulator" adjustment. Nebraska's legislature has not passed copay accumulator prohibition laws as of 2025, so patients should verify their specific plan documents before counting on the savings card to eliminate their out-of-pocket cost entirely.

Is Compounded Flibanserin Legal in Nebraska?

Yes. Compounded flibanserin prepared by a licensed 503A compounding pharmacy is legal in Nebraska, provided the pharmacy holds a valid Nebraska Board of Pharmacy license and compounds the preparation pursuant to a valid patient-specific prescription from a licensed prescriber.

503A refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare drug products for individual patients based on a prescription. The FDA's framework for 503A compounders permits compounding of flibanserin because the active pharmaceutical ingredient (API) is commercially available and not on the FDA's "do not compound" list [5].

Compounded flibanserin is not bioequivalent-tested against branded Addyi, and the FDA has not approved any compounded version. A prescriber who orders compounded flibanserin is doing so under the 503A framework, accepting that the product lacks the branded drug's pharmacokinetic data beyond the API itself.

Cost is the primary reason patients seek compounded flibanserin. Nebraska 503A pharmacies charge anywhere from $40 to $150 per month for a compounded flibanserin preparation, compared with the $880 list price for branded Addyi. That cost difference is large enough that some clinicians at HealthRX routinely discuss compounding as a first-line option for uninsured or underinsured patients.

The HealthRX clinical team uses a three-tier cost ladder for Nebraska patients prescribed flibanserin:

• Tier 1. Commercially insured with formulary coverage plus savings card. Target out-of-pocket: $0 to $50/month.
• Tier 2. Commercially insured without formulary coverage, savings card eligible. Target out-of-pocket: $0 to $200/month after appeal.
• Tier 3. Uninsured, Medicaid only, or savings-card ineligible. Compounded flibanserin from a licensed Nebraska 503A pharmacy. Target out-of-pocket: $40 to $150/month.

This ladder is applied before writing any flibanserin prescription so the patient's access plan is clear at the point of care.

Telehealth Prescribing of Addyi in Nebraska: What the Rules Require

Nebraska permits telehealth prescribing of flibanserin. A Nebraska-licensed prescriber may evaluate a patient via synchronous audio-video telehealth and, if appropriate, issue a prescription for Addyi or compounded flibanserin without an in-person visit, as long as the prescriber holds REMS certification for Addyi.

The FDA's Addyi REMS program requires prescribers to counsel patients about the alcohol interaction and document that counseling before the prescription is dispensed [2]. That counseling can be completed during a telehealth visit and documented in the chart.

Nebraska telehealth law (Neb. Rev. Stat. § 71-8505) does not create a separate prescribing standard for controlled or REMS-program drugs beyond federal requirements. Since flibanserin is not a controlled substance, Nebraska's controlled substance telehealth rules do not apply. The prescriber must still establish a valid prescriber-patient relationship, which under Nebraska Board of Health guidelines requires at minimum a synchronous real-time interaction.

HealthRX providers who prescribe flibanserin for Nebraska patients complete the REMS certification, conduct a synchronous audio-video intake visit, review alcohol use history, confirm the HSDD diagnosis meets the FDA label criteria (acquired, generalized, premenopausal), and send the prescription to either a REMS-certified retail pharmacy or a licensed Nebraska 503A compounder based on the patient's cost tier.

The Clinical Evidence Behind Flibanserin: What Nebraska Patients Should Know

Flibanserin's mechanism differs from any other approved treatment for sexual dysfunction. It acts as a serotonin 1A agonist and serotonin 2A antagonist, modulating dopamine and norepinephrine release in the prefrontal cortex rather than acting on genital blood flow the way phosphodiesterase inhibitors do in men [1].

The BEGONIA trial (N=949, published in the Journal of Sexual Medicine in 2014) remains one of the primary efficacy references cited in the FDA label. Premenopausal women with HSDD who received flibanserin 100 mg nightly for 24 weeks reported 0.5 additional SSEs per 28-day period compared with placebo, a Female Sexual Function Index (FSFI) desire domain score improvement of 0.3 points, and a reduction in distress on the Female Sexual Distress Scale-Revised (FSDS-R) of approximately 8 points versus placebo (P<0.001 for all three endpoints) [1].

A 2016 Cochrane systematic review of five flibanserin trials (N=5,914 women) concluded that treatment increased SSEs by approximately 0.49 per month compared to placebo and reduced distress scores, while noting adverse events of dizziness, somnolence, nausea, and fatigue were more common with active drug [6]. Adverse event rates were highest in patients who consumed alcohol concurrently, which is why the REMS program requires documented alcohol counseling [2].

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy does not list flibanserin as a hormonal therapy, but does acknowledge its FDA approval for premenopausal HSDD and notes that clinicians should distinguish HSDD from sexual dysfunction secondary to genitourinary syndrome of menopause, where local estrogen therapy is preferred [7]. Nebraska prescribers evaluating patients for Addyi candidacy should complete this differential before initiating treatment.

Contraindications relevant to Nebraska prescribers include: concurrent use of moderate or strong CYP3A4 inhibitors (e.g., fluconazole, clarithromycin), hepatic impairment, and current alcohol use [2]. The drug is not indicated for postmenopausal women or men.

How Flibanserin Compares to Bremelanotide (Vyleesi) on Cost and Coverage in Nebraska

Bremelanotide (Vyleesi), the second FDA-approved pharmacotherapy for HSDD, is a subcutaneous injection taken on demand rather than nightly. Its list price is approximately $1,000 per dose in 2026, making it more expensive per-use for patients who have sexual activity more than once monthly [8].

Nebraska Medicaid does not cover bremelanotide either. Commercial coverage patterns are similar to Addyi: Tier 3 or Tier 4 placement, prior authorization required. No compounded version of bremelanotide is available from 503A pharmacies because the peptide API does not meet standard 503A sourcing criteria under current FDA guidance.

For Nebraska patients with no insurance coverage for either agent, compounded flibanserin is the only pharmacotherapy option with a meaningfully lower cost than the branded alternatives.

Nebraska Pharmacy Availability and Practical Filling Steps

Not every Nebraska pharmacy is REMS-certified to dispense Addyi. Large chain pharmacies including CVS, Walgreens, and Rite Aid are enrolled in the REMS program at many locations, but individual store participation can vary. Smaller independent pharmacies may not be enrolled.

Before sending a prescription, the prescribing provider should confirm with the dispensing pharmacy that:

1. The pharmacist is REMS-certified for Addyi.
2. The pharmacy has current stock (Addyi is not a high-volume item and may need to be special-ordered with 24-48 hours lead time).
3. The patient's savings card or insurance has been processed ahead of dispensing to avoid a surprise $880 charge at pickup.

For patients using a 503A compounding pharmacy, the pharmacy does not need REMS certification because it is compounding a patient-specific preparation rather than dispensing the branded product. The prescriber still needs REMS certification if writing branded Addyi; if the prescription is written specifically for compounded flibanserin API, the prescriber's REMS certification requirement is specific to branded Addyi dispensing. Prescribers should consult their REMS certification terms directly.

Mail-order is available for branded Addyi through REMS-enrolled specialty mail pharmacies, which may offer marginally lower dispensing fees for Nebraska patients in rural areas where local REMS-certified pharmacies are sparse.

Monitoring and Follow-Up for Nebraska Patients on Flibanserin

The FDA label recommends evaluating response at 8 weeks. If a patient has not shown improvement in SSEs or reduction in distress after 8 weeks of nightly 100 mg dosing, continuing the drug is unlikely to be beneficial [2].

The Journal of Sexual Medicine's clinical practice guidelines for female sexual dysfunction suggest using validated outcome measures such as the FSFI and the FSDS-R at baseline and at the 8-week follow-up visit rather than relying solely on patient self-report [1]. For Nebraska telehealth patients, these tools can be administered as electronic questionnaires before each visit.

Side effects to monitor at follow-up: somnolence (reported in 11% of treated patients in Phase 3 trials), dizziness (11%), nausea (10%), and fatigue (9%) [2]. Patients who report next-day cognitive impairment should be advised not to drive until they know how the drug affects them.

Drug interactions are common enough to review at every visit. The FDA drug interaction database lists flibanserin as a CYP3A4 substrate. Any new prescription for a CYP3A4 inhibitor in a patient on flibanserin warrants immediate dose review or temporary discontinuation [5].